Multiple Sclerosis Relapses Following Cessation of Fingolimod

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10443036" target="_blank" >RIV/00064165:_____/22:10443036 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10443036

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ytPtKRErVP" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ytPtKRErVP</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40261-022-01129-7" target="_blank" >10.1007/s40261-022-01129-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Multiple Sclerosis Relapses Following Cessation of Fingolimod

Popis výsledku v původním jazyce

Background: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is known about modifiers of the risk of post-cessation relapse, including the delay to commencement of new therapy and prior disease activity. Objective: We aimed to determine the rate of relapse following cessation of fingolimod and to identify predictors of relapse following cessation. Methods: Data were extracted from the MSBase registry in March 2019. Inclusion criteria were (a) clinically definite relapsing multiple sclerosis, (b) treatment with fingolimod for &gt;= 12 months, (c) follow-up after cessation for &gt;= 12 months, and (d) at least one Expanded Disability Status Scale score recorded in the 12 months before cessation. Results: A total of 685 patients were identified who met criteria. The mean annualised relapse rate was 1.71 (95% CI 1.59, 1.85) in the year prior to fingolimod, 0.50 (95% CI 0.44, 0.55) on fingolimod and 0.43 (95% CI 0.38, 0.49) after fingolimod. Of these, 218 (32%) patients experienced a relapse in the first 12 months. Predictors of a higher relapse rate in the first year were: younger age at fingolimod cessation, higher relapse rate in the year prior to cessation, delaying commencement of new therapy and switching to low-efficacy therapy. Conclusions: Disease reactivation following fingolimod cessation is more common in younger patients, those with greater disease activity prior to cessation and in those who switch to a low-efficacy therapy.

Název v anglickém jazyce

Multiple Sclerosis Relapses Following Cessation of Fingolimod

Popis výsledku anglicky

Background: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is known about modifiers of the risk of post-cessation relapse, including the delay to commencement of new therapy and prior disease activity. Objective: We aimed to determine the rate of relapse following cessation of fingolimod and to identify predictors of relapse following cessation. Methods: Data were extracted from the MSBase registry in March 2019. Inclusion criteria were (a) clinically definite relapsing multiple sclerosis, (b) treatment with fingolimod for &gt;= 12 months, (c) follow-up after cessation for &gt;= 12 months, and (d) at least one Expanded Disability Status Scale score recorded in the 12 months before cessation. Results: A total of 685 patients were identified who met criteria. The mean annualised relapse rate was 1.71 (95% CI 1.59, 1.85) in the year prior to fingolimod, 0.50 (95% CI 0.44, 0.55) on fingolimod and 0.43 (95% CI 0.38, 0.49) after fingolimod. Of these, 218 (32%) patients experienced a relapse in the first 12 months. Predictors of a higher relapse rate in the first year were: younger age at fingolimod cessation, higher relapse rate in the year prior to cessation, delaying commencement of new therapy and switching to low-efficacy therapy. Conclusions: Disease reactivation following fingolimod cessation is more common in younger patients, those with greater disease activity prior to cessation and in those who switch to a low-efficacy therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Drug Investigation

ISSN

1173-2563

e-ISSN

1179-1918

Svazek periodika

42

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

10

Strana od-do

355-364

Kód UT WoS článku

000770497300001

EID výsledku v databázi Scopus

2-s2.0-85127113710